Phase 1 study of KT-333, a targeted protein degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia, and solid tumors

被引：0
|
作者：
Starodub, Alexander
Gollerkeri, Ashwin
De Savi, Chris
Dey, Joyoti
Agarwal, Sagar
Donohue, Sean
Perea, Rachelle
Klaus, Christine
Gollob, Jared
机构：
[1] Christ Hosp, Cincinnati, OH USA
[2] Kymera Therapeut, Watertown, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3171
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I study of sapacitabine, an oral nucleoside analogue, in patients with refractory solid tumors or lymphomas
    Tolcher, A.
    Calvo, E.
    Carmona, T.
    Patnaik, A.
    Papadopoulos, K.
    Gianella-Borradori, A.
    Chiao, J.
    Cohen, R.
    EJC SUPPLEMENTS, 2006, 4 (12): : 142 - 142
  • [32] PHASE I STUDY OF CABAZITAXEL IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SOLID TUMORS: A POETIC GROUP STUDY
    Manley, P.
    Trippett, T.
    Smith, A.
    Macy, M.
    Leary, S.
    Boklan, J.
    Cohen, K.
    Shen, L.
    Herzog, C.
    Veyrat-Follet, C.
    Zhang, J.
    Chi, S.
    PEDIATRIC BLOOD & CANCER, 2015, 62 : S157 - S158
  • [33] Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma
    Izutsu, Koji
    Yamamoto, Kazuhito
    Kato, Koji
    Ishikawa, Takayuki
    Fukuhara, Noriko
    Terui, Yasuhito
    Choi, Ilseung
    Humphrey, Kathryn
    Kim, Su Young
    Okubo, Sumiko
    Ogawa, Natsumi
    Nishimura, Yasuko
    Salem, Ahmed Hamed
    Maruyama, Dai
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (03) : 370 - 380
  • [34] Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma
    Koji Izutsu
    Kazuhito Yamamoto
    Koji Kato
    Takayuki Ishikawa
    Noriko Fukuhara
    Yasuhito Terui
    Ilseung Choi
    Kathryn Humphrey
    Su Young Kim
    Sumiko Okubo
    Natsumi Ogawa
    Yasuko Nishimura
    Ahmed Hamed Salem
    Dai Maruyama
    International Journal of Hematology, 2021, 113 : 370 - 380
  • [35] Initial Results of a Phase Ib Study of Ibrutinib in Combination with Obinutuzumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
    Davids, Matthew S.
    Kim, Haesook T.
    Savell, Alexandra
    Santiago-Medero, Carlos
    Francoeur, Karen
    Abramson, Jeremy S.
    Jacobsen, Eric D.
    LaCasce, Ann S.
    Fisher, David C.
    Brown, Jennifer R.
    BLOOD, 2017, 130
  • [36] Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study
    Doubek, Michael
    Brychtova, Yvona
    Panovska, Anna
    Sebejova, Ludmila
    Stehlikova, Olga
    Chovancova, Jana
    Malcikova, Jitka
    Smardova, Jana
    Plevova, Karla
    Volfova, Pavlina
    Trbusek, Martin
    Mraz, Marek
    Bakesova, Denisa
    Trizuljak, Jakub
    Hadrabova, Marketa
    Obrtlikova, Petra
    Karban, Josef
    Smolej, Lukas
    Oltova, Alexandra
    Jelinkova, Eva
    Pospisilova, Sarka
    Mayer, Jiri
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (05) : 417 - 421
  • [37] Final Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
    Badoux, Xavier C.
    Keating, Michael J.
    O'Brien, Susan
    Wierda, William G.
    Faderl, Stefan
    Estrov, Zeev
    Pasia, Manolo
    Lerner, Susan
    Sargent, Rachel L.
    Kantarjian, Hagop M.
    Ferrajoli, Alessandra
    BLOOD, 2011, 118 (21) : 448 - 448
  • [38] Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
    Fischer, Kirsten
    Cramer, Paula
    Busch, Raymonde
    Stilgenbauer, Stephan
    Bahlo, Jasmin
    Schweighofer, Carmen D.
    Boettcher, Sebastian
    Staib, Peter
    Kiehl, Michael
    Eckart, Michael J.
    Kranz, Gabriele
    Goede, Valentin
    Elter, Thomas
    Buehler, Andreas
    Winkler, Dirk
    Kneba, Michael
    Doehner, Hartmut
    Eichhorst, Barbara F.
    Hallek, Michael
    Wendtner, Clemens-Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (26) : 3559 - 3566
  • [39] VENETOCLAX IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY SOLID TUMORS: UPDATED FINDINGS FROM A PHASE 1 STUDY
    Morgenstern, Daniel
    Khaw, Seong
    Gerber, Nicolas
    Place, Andrew
    Corradini, Nadege
    Loh, Mignon
    Verschuur, Arnauld
    Ziegler, David
    Fraser, Chris
    Cooper, Todd
    Forlenza, Christopher
    O'Brien, Maureen
    Federico, Sara
    Van Eijkelenburg, Natasha
    Onishi, Maika
    Unnebrink, Kristina
    Chen, Xin
    Badawi, Mohamed
    Ghanim, Majd
    Palenski, Tammy
    Goldsmith, Kelly
    PEDIATRIC BLOOD & CANCER, 2022, 69
  • [40] Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)
    Wendtner, Clemens
    Hillmen, Peter
    Mahadevan, Daruka
    Stilgenbauer, Stephan
    Uharek, Lutz
    Coutre, Steven
    Frankfurt, Olga
    Bloor, Adrian
    Bosch, Francesc
    Furman, Richard R.
    Kimby, Eva
    Gribben, John G.
    Gobbi, Marco
    Dreisbach, Luke
    Hurd, David Duane
    Sekeres, Mikkael A.
    Ferrajoli, Alessandra
    Shah, Sheetal
    Zhang, Jennie
    de Parseval, Laure Moutouh
    Chanan-Khan, Asher A.
    BLOOD, 2010, 116 (21) : 591 - 592
12345